Service members train intensely and carry heavy gear, putting repeated strain on their muscles and joints. Persistent pain after deployment can make the return to everyday life more difficult. Ibuprofen is a familiar option: A 2024 Military Medicine study of 30,012 service members seen by clinical pharmacists placed it among the ten most frequently prescribed medications.
At Naval Medical Center San Diego, a Navy Phase 2 trial was designed to test palmitoylethanolamide (PEA) for chronic inflammatory pain, according to the ClinicalTrials.gov record. Its randomized, placebo-controlled protocol examines the compound in a military pain-care setting. Below, supplement company Neurogan Health reviews the placebo-controlled study and what it says about PEA’s potential.
The ClinicalTrials.gov record describes a randomized Phase 2 trial sponsored by Navy Medical Center San Diego. It planned to assign participants to PEA at 600 milligrams twice daily or a visually identical placebo for eight weeks. The listing identifies Dr. Brian McLean as principal investigator and sets a target enrollment of 80 participants. Its primary outcome is pain level, assessed at weeks four and eight.
The entry was last updated Aug. 15, 2024, and lists estimated completion in October 2025. It has no posted results. Because the record has not been updated since then, it does not establish whether recruitment continues. The trial is research; its results alone would not change military treatment protocols or establish PEA as an approved replacement for standard pain relievers.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug family, or NSAIDs, commonly used for aches, fever, and inflammation. It reduces pain and swelling by limiting the body’s production of chemicals involved in those responses, according to the National Library of Medicine. Its availability and familiarity help explain its widespread use for short-term aches and inflammation.
Regular or high-dose use carries risks. The National Library of Medicine warns about ulcers and gastrointestinal bleeding, as well as heart attack and stroke risks that may rise with dosage and duration. NSAIDs can also strain the kidneys, especially during dehydration; the National Institute of Diabetes and Digestive and Kidney Diseases explains that dehydration raises kidney-injury risk when taking them.
Hydration, injury, and recovery can all matter in demanding environments. These risks do not make NSAIDs unsuitable for everyone, but they underscore the need for individualized pain care.
VA/DoD pain guidance describes chronic care as broader than medication alone, including self-management and physical or behavioral therapies. It frames success around pain control and function. For PEA, researchers must establish where it might fit into care for service members and how its benefits and risks vary by dose.
PEA is a fatty acid amide, a signaling molecule that the body produces in response to tissue stress or injury and that is involved in regulating inflammation. Its natural presence does not prove that supplements relieve pain.
“Ultramicronized” describes a process that reduces particle size. Because PEA dissolves poorly in water, smaller particles may disperse more readily. The formulation is intended to affect absorption, but that does not establish better outcomes.
A 2023 systematic review in the journal Nutrients pooled 11 trials with 774 patients across different chronic pain conditions. Combined findings favored PEA, but the studies differed in diagnosis, formulation, dose, and duration. Some found no significant advantage over a comparator.
Most treatment periods were eight to 12 weeks, though one study lasted a year. The review also identified two company-funded trials and two with company-supplied medication.
A 2024 review, also published in Nutrients, found improvement associated with longer use, but eight of its nine studies lacked control groups. Those changes cannot isolate PEA’s effect from other care or natural fluctuation.
There is at least one direct comparison of PEA to ibuprofen in a different setting. In a 2022 randomized trial published in Food and Nutrition Sciences, researchers studied 94 adults with tension headaches and compared a bioavailable PEA formulation with ibuprofen. That preliminary acute-headache result does not establish long-term effects in service members with chronic pain. Some authors were affiliated with the ingredient company.
A 2016 review in the British Journal of Clinical Pharmacology found long-term safety evidence limited. The Navy study could add evidence from a military clinic, depending on its design and results.
For PEA to become a credible pain-care option, evidence must show meaningful improvement in pain or function, safety over time, and consistent results across service members. Researchers would also need to assess whether effects persist and whether side effects differ by dose. Any future guidance would weigh those results alongside other available treatments.
The findings would point toward different next steps:
Publication would prompt further review. VA and Defense Department guideline developers assess and grade clinical evidence before changing recommendations. Regulatory decisions are separate: the FDA does not approve supplements for safety and effectiveness before sale. A trial alone cannot establish approval or change military practice.
Pain care aims to restore function, not just lower a score. “The goal is to improve overall functioning and enhance quality of life,” said Amanda Brooks, a doctor of physical therapy who manages Columbia VA’s Active Management of Pain program, in January 2025. The program combines physical therapy and behavioral strategies.
Research also needs to clarify which treatments help which patients. “We wanted to learn which chronic pain therapies work for veterans and in which settings they work better,” said Collin Calvert, a Minneapolis VA investigator and statistician, in an August 2025 report about complementary pain therapies. Neither was commenting on PEA. Their remarks underscore the importance of function and patient-specific care.
For next steps, watch for a registry update clarifying the study’s status and for any published results. Reports should describe pain, function, and safety outcomes, and whether the findings warrant further testing.
The central question is whether PEA can offer reliable relief as part of military pain care. An alternative must work in the settings and conditions where service members need it. A credible answer will depend on the trial’s design and results, and on further evidence showing whether its findings hold up in practice.
This story was produced by Neurogan Health and reviewed and distributed by Stacker.
